Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Jiangsu Hengrui Pharmaceuticals Co. Ltd. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 7 examiners and 7 art units, so the portfolio presents a broad set of prosecution interfaces rather than a single recurring examination relationship.
KOSACK, JOSEPH R is the busiest examiner, with 1 pending matter. Because the pending matters are spread across the same number of examiners and art units, no examiner or art unit carries a larger visible share of the workload. Counsel should maintain matter-specific strategies while tracking recurring pharmaceutical claim, written-description, and prior-art themes across the separate assignments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §102 only | 1 (14%) |
| §112 only | 3 (43%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSACK, JOSEPH R | 1 | 74.8% | -6.1% |
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
| SAMALA, JAGADISHWAR RAO | 1 | 67.9% | +55.7% |
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546071 | SMTP-7 DERIVATIVE AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 46d |
| 18287244 | CAPSULE FOR SPECIFIC DRUG DELIVERY AND PREPARATION METHOD THEREFOR | TCHERKASSKAYA, OLGA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546071 | SMTP-7 DERIVATIVE AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 46d |
| 18728162 | PHARMACEUTICAL COMPOSITION COMPRISING NEUROKININ-1 ANTAGONIST PRODRUG COMPOUND | RICCI, CRAIG D | — |
| 18707429 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | CHEN, PO-CHIH | — |
| 18687804 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | SAMALA, JAGADISHWAR RAO | — |
| 18287244 | CAPSULE FOR SPECIFIC DRUG DELIVERY AND PREPARATION METHOD THEREFOR | TCHERKASSKAYA, OLGA V | — |
| 18265217 | MULTISPECIFIC ANTIGEN BINDING PROTEIN | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1611 | 1 |
| 1621 | 1 |
| 1618 | 1 |
| 1615 | 1 |
| 1622 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18867628 | CRYSTAL FORMS OF TRIAZINE DIONE DERIVATIVE AND PREPARATION METHOD THEREFOR | KOSACK, JOSEPH R | 3991 | §112 | Non-Final OA | — | Pending | Nov 20, 2024 |
| 18728162 | PHARMACEUTICAL COMPOSITION COMPRISING NEUROKININ-1 ANTAGONIST PRODRUG COMPOUND | RICCI, CRAIG D | 1611 | §103§112DP | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18707429 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | CHEN, PO-CHIH | 1621 | §112 | Final Rejection | — | Pending | May 03, 2024 |
| 18687804 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | SAMALA, JAGADISHWAR RAO | 1618 | §112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18287244 | CAPSULE FOR SPECIFIC DRUG DELIVERY AND PREPARATION METHOD THEREFOR | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18546071 | SMTP-7 DERIVATIVE AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | 46d | Pending | Aug 10, 2023 |
| 18265217 | MULTISPECIFIC ANTIGEN BINDING PROTEIN | HADDAD, MAHER M | 1641 | §102 | Final Rejection | — | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiangsu Hengrui Pharmaceuticals Co. Ltd. has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Joseph R Kosack has the most, with 1 of Jiangsu Hengrui Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
